

Appl. No. 10/817,449
Amendment
Page 2

RECEIVED
CENTRAL FAX CENTER
MAR 05 2007

Amendments to the Specification:

Please amend the paragraph beginning at the bottom of page 14 and extending onto the top of page 15, as follows:

The term "effective amount" means an amount of at least one compound of formula 1, 2, 3A, 3B, 3C, 4A and/or 4B, or a pharmaceutically acceptable salt of such compound, that is effective to treat (e.g., prevent the occurrence or treat after the occurrence of) bladder or urinary tract cancer. The specific dose of compound administered according to this invention to obtain therapeutic or abrogatory effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, the condition being treated and the individual host or patient being treated. An exemplary daily dose (administered in single or divided doses) contains a dosage level of from about 0.01 mg/kg to about 100 mg/kg of body weight of a compound of this invention. Preferred daily doses generally are from about 0.05 mg/kg to about 50 mg/kg and, more preferably, from about 0.1 mg/kg to about 25 mg/kg. Furthermore, the compounds of this invention, with their strong antioxidant action and bladder cancer inhibitory potential, cisplatin, carboplatin, taxanes such as paclitaxel and docetaxel, gemcitabine, ifosfamide, ~~and the methotrexate and its analogues~~ such as trimetrexate and piritrexim, thiotepe, doxorubicin (adriamycin Adriamycin®, Pharmacia & Upjohn, Kalamazoo, Michigan), mitomycin may be used additively or synergistically with current therapeutic agents, including and most commonly used combination therapies used to prevent recurrence and progression, particularly of superficial tumors (75% of all bladder cancers).